Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN D BECKES

Allopathic & Osteopathic Physicians Hospitalist

NPI
1639118912
CMS profile
836653
Location
NATIONAL CITY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$570.95

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $570.95 10

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $570.95 10

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN D BECKES

NPI 1639118912 · CMS profile ID 836653

Allopathic & Osteopathic Physicians / Hospitalist

NATIONAL CITY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639118912?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN D BECKES, NPI 1639118912, CMS profile ID 836653. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639118912?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JOHN D BECKES, NPI 1639118912, CMS profile ID 836653. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639118912?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JOHN D BECKES, NPI 1639118912, CMS profile ID 836653, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1639118912?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $570.95 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $34.9906/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141729882 CMS
Merck Sharp & Dohme LLC $29.9906/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141729886 CMS
Merck Sharp & Dohme LLC $48.0306/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141730068 CMS
Merck Sharp & Dohme LLC $121.0106/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141729884 CMS
Merck Sharp & Dohme LLC $64.9905/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141730078 CMS
Merck Sharp & Dohme LLC $27.7405/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141730080 CMS
Merck Sharp & Dohme LLC $39.9805/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141879371 CMS
Merck Sharp & Dohme LLC $115.6805/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141730082 CMS
Merck Sharp & Dohme LLC $23.5505/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141730084 CMS
Merck Sharp & Dohme LLC $64.9905/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141882468 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $124.99 1
PY2023 $3,065.23 9
PY2024 $570.95 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,605,177.75 703
PY2024 Recipient $1,613.98 3
PY2024 Principal investigator $3,238,637.82 219
PY2023 Recipient $1,016.73 1
PY2023 Principal investigator $5,966,992.99 5,656
PY2022 Recipient $456.00 1
PY2022 Principal investigator $3,684,980.58 3,955

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023 · part 1 of 2

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

5,000 records in this part · 5,657 in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $123,447.53 12/31/2023 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults No dispute reported 06/30/2026 1042570223
Principal investigator 1 Janssen Research & Development, LLC $670.00 12/22/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129605
Principal investigator 1 ModernaTX, Inc. $5,265.42 12/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041143751
Principal investigator 1 ModernaTX, Inc. $11,871.54 12/20/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1041143765
Principal investigator 1 ModernaTX, Inc. $288.00 12/15/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041141857
Principal investigator 1 ModernaTX, Inc. $546.48 12/15/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041143723
Principal investigator 1 ModernaTX, Inc. $250.00 12/15/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041143737
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118707
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118721
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118735
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041118749
Principal investigator 1 ModernaTX, Inc. $1,116.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118763
Principal investigator 1 ModernaTX, Inc. $3,368.64 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118789
Principal investigator 1 ModernaTX, Inc. $2,195.10 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118804
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118831
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118845
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118859
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118873
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118887
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118901
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118915
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118929
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118943
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118955
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118973
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041118987
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119001
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119015
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041119029
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041119045
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041119059
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041119073
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041119087
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041119101
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041119113
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041119127
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119141
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119155
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119167
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119177
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119193
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119209
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119223
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119237
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119253
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119263
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119281
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119295
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119309
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119323
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119337
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119351
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119365
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119379
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119393
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119407
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119421
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119435
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119449
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119463
Principal investigator 1 ModernaTX, Inc. $1,116.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119477
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119491
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119505
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119517
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119534
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119549
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119563
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119577
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119591
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119603
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119619
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119633
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119649
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119663
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119677
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119691
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119705
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119719
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119737
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119751
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119765
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041119779
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041119793
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041119807
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041119821
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041119835
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041119849
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119877
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119891
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119905
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119917
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119932
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119947
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119959
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119975
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041119989
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120001
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120015
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120029
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041120043
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041120057
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120101
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120115
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120129
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120143
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120157
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120171
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120185
Principal investigator 1 ModernaTX, Inc. $2,166.21 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041120201
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120223
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120237
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120251
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120267
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120283
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120299
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120311
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120327
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120341
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120355
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120369
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120383
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120397
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120413
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120427
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120441
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120455
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120469
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120483
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120497
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120513
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120529
Principal investigator 1 ModernaTX, Inc. $1,116.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120541
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120555
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120571
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120586
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041120599
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041120615
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041120629
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041120641
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041120657
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041120673
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041120687
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041120701
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041120713
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120727
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120743
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120757
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120769
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120789
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120803
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120817
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120831
Principal investigator 1 ModernaTX, Inc. $1,116.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120845
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120859
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120873
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120887
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120901
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120917
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120933
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120947
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120959
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120975
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041120989
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121003
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121019
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121033
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121049
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121063
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121075
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121089
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121103
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121117
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121133
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121147
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121161
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121175
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121189
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121203
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121217
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121231
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121245
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121259
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121273
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121287
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121301
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121315
Principal investigator 1 ModernaTX, Inc. $2,166.21 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041121329
Principal investigator 1 ModernaTX, Inc. $2,166.21 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041121343
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121359
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121373
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121387
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121403
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121417
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121433
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121447
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121461
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121475
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121489
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121507
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121521
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121537
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121551
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121565
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121579
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121593
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121607
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121623
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121639
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121649
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121663
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121677
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121691
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121707
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121721
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121735
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121749
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121763
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121777
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121791
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121807
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041121821
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121867
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121881
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121895
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121911
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121925
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121939
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121951
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121969
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121983
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041121999
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122011
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122025
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122039
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122053
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122069
Principal investigator 1 ModernaTX, Inc. $1,116.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122083
Principal investigator 1 ModernaTX, Inc. $1,116.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122095
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122109
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122123
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122139
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122155
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122169
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122183
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122199
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122213
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122225
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122241
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122255
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122269
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122283
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122299
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122313
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122327
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122343
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122357
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122371
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122385
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122399
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122413
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122427
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122443
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122459
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122473
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122489
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122503
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122515
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122531
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122545
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122559
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122575
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122589
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122603
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122619
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122633
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122647
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122661
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122675
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122689
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122703
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122717
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122731
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122745
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122761
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122775
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122791
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122807
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122821
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122835
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122849
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041122863
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122877
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122891
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122905
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122921
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122937
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122951
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122965
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122979
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041122993
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123008
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123021
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123041
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123055
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123069
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123083
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123097
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123111
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123125
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123141
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123155
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123169
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123187
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123201
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123215
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123229
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123243
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123257
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123271
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123286
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123299
Principal investigator 1 ModernaTX, Inc. $1,116.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123315
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123329
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123343
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123357
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123371
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123387
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123403
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123417
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123431
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123445
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123459
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123473
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123487
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123501
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123515
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123529
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123545
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123561
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123575
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123591
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123605
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123619
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123633
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123647
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123661
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123675
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123689
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123703
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123720
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123735
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123749
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041123763
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123807
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123821
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123835
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123849
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123861
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123877
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123891
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123907
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123919
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123933
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123949
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123963
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123977
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041123993
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124007
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124021
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124035
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124051
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124065
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124079
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124093
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124107
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124121
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124137
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124152
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124167
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124183
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124197
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124211
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124225
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124239
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041124253
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041124267
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041124281
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041124295
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041124309
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041124326
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041124343
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124355
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124371
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124383
Principal investigator 1 ModernaTX, Inc. $1,116.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124397
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124409
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124423
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124439
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041124451
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041124465
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041124481
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041124497
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041124511
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041124525
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041124539
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124567
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124585
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124597
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124615
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124629
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124643
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124659
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124673
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124687
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124701
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124715
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124729
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124743
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124757
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124771
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124787
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041124801
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124847
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124861
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124875
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124889
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124903
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124917
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124931
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124945
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124959
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124973
Principal investigator 1 ModernaTX, Inc. $1,116.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041124987
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125001
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125017
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125029
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125047
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125061
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125075
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125089
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125103
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125117
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125133
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125147
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125159
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125177
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125193
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125207
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125221
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125235
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125249
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125263
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125277
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125293
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125307
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125321
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125335
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125351
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125365
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125379
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125395
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125409
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125423
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125439
Principal investigator 1 ModernaTX, Inc. $2,166.21 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041125453
Principal investigator 1 ModernaTX, Inc. $2,166.21 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041125467
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125481
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125495
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125509
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125523
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125537
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125551
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125565
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125579
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125593
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125608
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125621
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125637
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125651
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125665
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125679
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125693
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125707
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125721
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125737
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125751
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125765
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125779
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125791
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125799
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041125815
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125829
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125843
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125857
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125871
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125891
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125905
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125916
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125929
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125943
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125957
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125969
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125985
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041125999
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126012
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126027
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126043
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126057
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126101
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126115
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126129
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126143
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126157
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126171
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126185
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126199
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126213
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126227
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126241
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126255
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126269
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126287
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126301
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126315
Principal investigator 1 ModernaTX, Inc. $1,116.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126329
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126341
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126355
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126371
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126385
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126399
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126413
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126427
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126441
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126455
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126473
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126487
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126499
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126513
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126527
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126541
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126555
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041126569
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126585
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126599
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126611
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126623
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126641
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126653
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126673
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126681
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126695
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126709
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126721
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126735
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126748
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126759
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126773
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126785
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126799
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126813
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126827
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126841
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126859
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126869
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126885
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126901
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126913
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126927
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126943
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126955
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126971
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041126987
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127001
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127013
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127029
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127043
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127059
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127073
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127087
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127101
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127115
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127129
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127143
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127157
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127171
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127185
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127199
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127213
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127227
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127241
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127257
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127271
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127287
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127301
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127315
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041127329
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041127341
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041127357
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041127375
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041127387
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041127403
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041127417
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041127431
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041127446
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041127461
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041127475
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127489
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127503
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127519
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127533
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127547
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127561
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127575
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127589
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127603
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127615
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127628
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127641
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127655
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127669
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127683
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127697
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127713
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127725
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127739
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127753
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127767
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127785
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127799
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127813
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127827
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127841
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127855
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127869
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127883
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127897
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127913
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127927
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127941
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127955
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127969
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127983
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041127997
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128011
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128025
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128039
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128053
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128067
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128081
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128095
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128107
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128121
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128135
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128147
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128165
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128183
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128197
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128211
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128223
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128239
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128253
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128267
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128281
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128295
Principal investigator 1 ModernaTX, Inc. $2,166.21 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041128309
Principal investigator 1 ModernaTX, Inc. $2,166.21 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041128323
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128337
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128351
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128365
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128381
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128397
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128409
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128423
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128439
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128453
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128467
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128481
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128495
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128509
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128523
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128537
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128551
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128565
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128579
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128593
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128607
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128623
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128637
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128651
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128665
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128679
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128695
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128709
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128723
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128737
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128751
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128764
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128777
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128791
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128805
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128817
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128831
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128845
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128863
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128877
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128889
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128903
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128919
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128931
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128949
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041128961
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128975
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041128993
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129005
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129017
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129031
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129045
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129063
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129079
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129093
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129106
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129123
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129135
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041129149
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041129163
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041129177
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041129191
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041129205
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041129219
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041129233
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041129247
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041129263
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041129275
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041129289
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129319
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129335
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129349
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129363
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129379
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129393
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129407
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129421
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129435
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129449
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129465
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129479
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129493
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129505
Principal investigator 1 ModernaTX, Inc. $1,116.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129519
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129534
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129547
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129561
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129575
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129587
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129601
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129615
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129627
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129641
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129655
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129669
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129683
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129697
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041129711
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041129725
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041129739
Principal investigator 1 ModernaTX, Inc. $2,166.21 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041129755
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129783
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129797
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129811
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129827
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129841
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129855
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129869
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129883
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129897
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129912
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129927
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129941
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129953
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129967
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041129983
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130001
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130015
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130029
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130043
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130057
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130073
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130087
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130101
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130115
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130129
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130145
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130161
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130175
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130185
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130199
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130211
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130227
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130242
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130257
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130271
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130285
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130299
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130313
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130327
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130339
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130355
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130369
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130383
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130395
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130411
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130425
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130439
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130451
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130467
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130485
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130499
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130513
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130527
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130541
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130555
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130569
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130597
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130611
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130625
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130639
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130653
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130665
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130677
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130695
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130709
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130723
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130735
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130749
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130765
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130779
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130793
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130807
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041130819
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130831
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130845
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130861
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130878
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130893
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130907
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130923
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130937
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041130951
Principal investigator 1 ModernaTX, Inc. $2,166.21 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041130965
Principal investigator 1 ModernaTX, Inc. $2,166.21 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041130979
Principal investigator 1 ModernaTX, Inc. $1,116.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131023
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131037
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131051
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131065
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131079
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131093
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131107
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131121
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131135
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131151
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131165
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131179
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131193
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131207
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131221
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131237
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131249
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131267
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131281
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131293
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131309
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131321
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131337
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131349
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131363
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131377
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131393
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131403
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131415
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041131429
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041131443
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041131459
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041131471
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041131485
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041131499
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041131513
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041131527
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041131543
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041131557
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041131571
Principal investigator 1 ModernaTX, Inc. $2,166.21 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041131585
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131629
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131645
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131659
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131675
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131691
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131705
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131719
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131733
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131747
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131761
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131777
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131795
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131809
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131823
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131837
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131853
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131867
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131881
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131895
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131909
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131925
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131939
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131955
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131971
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131983
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041131997
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132013
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132029
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132045
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132059
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132073
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132087
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132101
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132117
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132131
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132145
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132158
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132173
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132187
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132201
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132219
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132235
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132251
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132265
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132279
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132293
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132307
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132321
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132335
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132349
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132362
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132377
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132391
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132407
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132421
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132435
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132451
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132465
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132479
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132493
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132509
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132521
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132551
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132565
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132579
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132593
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132607
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132621
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132635
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132647
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132661
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132675
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132689
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132703
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132719
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132733
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132747
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132761
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132779
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132793
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132807
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041132821
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132867
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132881
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132896
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132911
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132925
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132939
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132951
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132965
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132979
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041132997
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133011
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133027
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133041
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133057
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133071
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133085
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133102
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133119
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133129
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133143
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133157
Principal investigator 1 ModernaTX, Inc. $1,116.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133175
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133189
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133201
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133215
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133231
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133245
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133263
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133277
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133293
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133307
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133321
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133335
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133349
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133367
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133383
Principal investigator 1 ModernaTX, Inc. $2,166.21 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041133397
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133415
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133431
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133445
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133459
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133473
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133487
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133503
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133519
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133533
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133547
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133561
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133577
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133591
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133605
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133619
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133633
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133649
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133663
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133677
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133691
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133705
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133719
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133735
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133749
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133763
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133777
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133791
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133805
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133819
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133833
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041133847
Principal investigator 1 ModernaTX, Inc. $2,166.21 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041133861
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133875
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133893
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133907
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133921
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133935
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133949
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133963
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133977
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041133991
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134005
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134019
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134033
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134047
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134063
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134077
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134091
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134105
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134119
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134133
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134147
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134161
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041134175
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041134189
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041134205
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041134223
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041134235
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134265
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134279
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134289
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134301
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134315
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134329
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134343
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134357
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134369
Principal investigator 1 ModernaTX, Inc. $1,116.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134383
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134395
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134407
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134417
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134431
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134441
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134453
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134467
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134481
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134497
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134511
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134524
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134539
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134551
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134567
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134581
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134595
Principal investigator 1 ModernaTX, Inc. $2,166.21 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041134609
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134623
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134637
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134651
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134667
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134681
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134697
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134711
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134727
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134741
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134755
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134769
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134783
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134797
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134813
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134827
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134841
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134859
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134873
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134887
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134901
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134913
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134927
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134943
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134957
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134975
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041134989
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135003
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135017
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135031
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135047
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135061
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135075
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135091
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135103
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135119
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135131
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135145
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135159
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135175
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135187
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135203
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135217
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135231
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135245
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135261
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135275
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135289
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135305
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135319
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135333
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135347
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135361
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041135375
Principal investigator 1 ModernaTX, Inc. $2,166.21 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041135389
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135417
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135431
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135445
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135459
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135477
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135491
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135505
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135519
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041135533
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136247
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136263
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136277
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136291
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136305
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136319
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136333
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136347
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136361
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136379
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136395
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136409
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136423
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136437
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136451
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136465
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136477
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136507
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136521
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136535
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136551
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136567
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136581
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136595
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136611
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136625
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136639
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136653
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136667
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136681
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136695
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136709
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136725
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136739
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136753
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136767
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136785
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136795
Principal investigator 1 ModernaTX, Inc. $1,717.59 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136813
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136827
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136843
Principal investigator 1 ModernaTX, Inc. $576.84 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136857
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136871
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136885
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136899
Principal investigator 1 ModernaTX, Inc. $13.50 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041136917
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041136933
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041136947
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041136965
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041136979
Principal investigator 1 ModernaTX, Inc. $742.44 12/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041136993
Principal investigator 1 GRT US Holding, Inc. $2,585.00 12/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054199689
Principal investigator 1 GRT US Holding, Inc. $4,000.00 12/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054199731
Principal investigator 1 PFIZER INC. $117.40 12/11/2023 Non-covered Recipient Entity
Acclaim Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046274217
Principal investigator 1 PFIZER INC. $7.52 12/09/2023 Non-covered Recipient Entity
Acclaim Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045927377
Principal investigator 1 PFIZER INC. $403.92 12/07/2023 Non-covered Recipient Entity
Acclaim Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046042109
Principal investigator 1 ModernaTX, Inc. $44,367.80 12/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1041143679
Principal investigator 1 ModernaTX, Inc. $6,589.86 12/04/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041143635
Principal investigator 1 ModernaTX, Inc. $1,000.00 12/04/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1041143651
Principal investigator 1 ModernaTX, Inc. $2,000.00 12/04/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1041143665
Principal investigator 1 GRT US Holding, Inc. $70.00 12/01/2023 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A SINGLEARM OPENLABEL PHASE III TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF INTRAARTICULAR INJECTIONS OF RTXGRT7039 IN SUBJECTS WITH MODERATE TO SEVERE PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187535
Principal investigator 1 Janssen Research & Development, LLC $788.80 11/29/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129627
Principal investigator 1 ModernaTX, Inc. $540.00 11/29/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1041141845
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041098245
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041098261
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041098275
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041098291
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041098307
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041098321
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098335
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041098349
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098365
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098379
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098391
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098407
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098423
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098441
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098455
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098469
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098483
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098497
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098513
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098527
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098541
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098555
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041098569
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041098584
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041098601
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041098615
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041098629
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041098689
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098705
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098719
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098733
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098749
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098763
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098777
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098791
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098807
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098821
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098835
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098849
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098863
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098877
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098889
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099691
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099705
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099721
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099735
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099749
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099763
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099779
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099793
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099807
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099821
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099835
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099849
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099863
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099877
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099891
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099905
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099919
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099933
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099947
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099964
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099979
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041099993
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100009
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100023
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100037
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100051
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100067
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100081
Principal investigator 1 ModernaTX, Inc. $1,959.24 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100095
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100111
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100123
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100137
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100151
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100165
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100179
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100196
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100211
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100225
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100239
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100253
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041100325
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041100341
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041100357
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041100371
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041100385
Principal investigator 1 ModernaTX, Inc. $1,262.70 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041100399
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041100413
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041100427
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041100441
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041100455
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041100469
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041100487
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041100501
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041100515
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100529
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100543
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100557
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100573
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100585
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100599
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100613
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100627
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100643
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100657
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100669
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100685
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100701
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100717
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100731
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100743
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100757
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100771
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100787
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100803
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100817
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100831
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100845
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100863
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100879
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100893
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100905
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100919
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100933
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100947
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100963
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100977
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041100995
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101009
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101025
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101039
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101053
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101067
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101083
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101097
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101111
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101125
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101139
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101151
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101167
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101183
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101199
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101211
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101225
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101237
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101251
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101265
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101279
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041101379
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041101395
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041101409
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041101423
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041101437
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041101451
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041101468
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041101481
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101495
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101509
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101523
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101537
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101551
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101565
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101579
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101595
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101609
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101625
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101639
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101653
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101669
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101683
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101695
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101709
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101724
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101739
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101753
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101767
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101781
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101795
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101809
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101825
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101841
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101857
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101869
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101885
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101899
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101913
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101929
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101943
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101957
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101971
Principal investigator 1 ModernaTX, Inc. $2,195.10 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041101985
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102001
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102013
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102027
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102041
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102057
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102073
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102085
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102101
Principal investigator 1 ModernaTX, Inc. $1,959.24 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102117
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102131
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102145
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102159
Principal investigator 1 ModernaTX, Inc. $1,959.24 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102173
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102187
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102201
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102215
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102229
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102243
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102257
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102273
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102287
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102301
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102315
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102329
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102343
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102359
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102373
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102385
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102399
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102413
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102427
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102441
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102457
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102471
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102487
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102501
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102515
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102529
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102543
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102557
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102571
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102587
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102601
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041102657
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041102673
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041102687
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041102701
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041102715
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041102729
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041102743
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041102759
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041102771
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041102786
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041102801
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041102819
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041102831
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102843
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102857
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102871
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102885
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102901
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102915
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102931
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102945
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102959
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102973
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041102987
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103001
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103015
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103029
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103043
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103057
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103071
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103085
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103099
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103113
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103129
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103143
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103157
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103171
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103187
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103201
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103215
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103229
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103243
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103257
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103271
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103287
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103299
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103313
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103327
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103341
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103355
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103371
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103383
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103396
Principal investigator 1 ModernaTX, Inc. $1,959.24 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103409
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103423
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103439
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103453
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103465
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103479
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103493
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103507
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103523
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103537
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103551
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103565
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103579
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103595
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103609
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103623
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103637
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103651
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103665
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103673
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103689
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103701
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103713
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103721
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103737
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103751
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103761
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103775
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103791
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103801
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041103815
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041103885
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041103899
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041103913
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041103929
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041103943
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041103958
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041103973
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041103987
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041104001
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041104015
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041104029
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104045
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104059
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104077
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104091
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104105
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104119
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104133
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104147
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104161
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104175
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104189
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104205
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104219
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104233
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104247
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104261
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104275
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104289
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104305
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104319
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104333
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104347
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104361
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104375
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104389
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104405
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104421
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104435
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104451
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104465
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104479
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104493
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104507
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104519
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104535
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104549
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104563
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104577
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104591
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104607
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104621
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104633
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104647
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104663
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104675
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104689
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104703
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104717
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104733
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104749
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104761
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104775
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041104789
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041104873
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041104887
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041104903
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041104919
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041104933
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041104947
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041104961
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041104978
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041104995
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041105009
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041105023
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105039
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105053
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105069
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105083
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105101
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105117
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105131
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105145
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105159
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105175
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105189
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105203
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105217
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105231
Principal investigator 1 ModernaTX, Inc. $2,195.10 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105247
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105261
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105275
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105291
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105305
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105321
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105335
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105349
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105363
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105377
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105393
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105407
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105423
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105439
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105453
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105467
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105481
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105495
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105509
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105523
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105537
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105551
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105565
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105579
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105595
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105609
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105623
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105635
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105649
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105665
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105679
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105697
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105711
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105725
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105739
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105753
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105767
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105781
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105795
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105809
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105825
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105837
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105855
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105869
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105883
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041105897
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041105967
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041105981
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041105995
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106015
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106031
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106045
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106059
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106074
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106089
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106103
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106119
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106133
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106149
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106163
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106177
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106191
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106205
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106221
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106235
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106249
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106263
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106277
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106291
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106303
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106319
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106333
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106347
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106365
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106379
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106393
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041106407
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106421
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106437
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106449
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106463
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106478
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106495
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106511
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106525
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106539
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106553
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106567
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106581
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106595
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106609
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106623
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106635
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106649
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106663
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106681
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106693
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106709
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106723
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106739
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106751
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106765
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106781
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106795
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106807
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106821
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106837
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106851
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106867
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106883
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106895
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106911
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106927
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106941
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106955
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106969
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106985
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041106999
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107015
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107029
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107043
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107057
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107071
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041107131
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107145
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107159
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107173
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107187
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107205
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107217
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107231
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107247
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107259
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107275
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107291
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107305
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107319
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107333
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107349
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107363
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107377
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107391
Principal investigator 1 ModernaTX, Inc. $2,166.21 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041107405
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107419
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107433
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107447
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107463
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107477
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107489
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107505
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107519
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107533
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107547
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107561
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107577
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107593
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107607
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107621
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107633
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107645
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107661
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107677
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107693
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107707
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107721
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107735
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107749
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107763
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107777
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107791
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107806
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107823
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107835
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107850
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107865
Principal investigator 1 ModernaTX, Inc. $1,959.24 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107883
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107899
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107913
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107927
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107941
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107957
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107975
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041107989
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108003
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108015
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108031
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108047
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108061
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108075
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108089
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108103
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108121
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108135
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108149
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108163
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108177
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108235
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108247
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108261
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108275
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108290
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108305
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108319
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108333
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108347
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108361
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108377
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108391
Principal investigator 1 ModernaTX, Inc. $1,959.24 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108405
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108417
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108431
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108447
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108461
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108475
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108489
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108501
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108515
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108531
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108547
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108561
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108577
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108591
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108605
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108621
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108633
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108647
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108663
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108675
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108691
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108705
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108719
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108733
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108747
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108761
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041108775
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108849
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108861
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108875
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108889
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108901
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108915
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108929
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108943
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108957
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108971
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041108985
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041109001
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041109013
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109027
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109035
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109051
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109067
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109079
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109093
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109107
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109121
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109135
Principal investigator 1 ModernaTX, Inc. $2,195.10 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109151
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109165
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109179
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109191
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109209
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109223
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109237
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109251
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109267
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109281
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109297
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109311
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109325
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109341
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109355
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109371
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109387
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041109401
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041109413
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041109427
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041109439
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041109453
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109473
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109487
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109501
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109517
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109533
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109547
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109561
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109577
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109591
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109605
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109619
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109633
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109647
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109661
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109677
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109691
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109705
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109719
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109733
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109749
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109763
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109777
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109793
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109805
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109821
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109835
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109849
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109863
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109875
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109889
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109903
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041109917
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041109975
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041109989
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110005
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110021
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110035
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110049
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110063
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110077
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110091
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110107
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110121
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110135
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110149
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110167
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110181
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110195
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110209
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110223
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110237
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110251
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110265
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110279
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110291
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110309
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110323
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110337
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110351
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110365
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110377
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110393
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110407
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110421
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110435
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110449
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110464
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110479
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110495
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110505
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110519
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110537
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041110553
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110565
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110581
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110595
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110609
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110623
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110641
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110655
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110669
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110685
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110699
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110713
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110727
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110741
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110755
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110771
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110787
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110801
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110815
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110831
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110847
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110861
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110875
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110889
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110905
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110919
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110935
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110951
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110965
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110979
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041110993
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111007
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111021
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111035
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111049
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111063
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111139
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111151
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111167
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111181
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111194
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111213
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111225
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111239
Principal investigator 1 ModernaTX, Inc. $1,959.24 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111255
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111269
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111285
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111299
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111313
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111325
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111337
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111351
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111361
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111375
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111389
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111401
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111415
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111431
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111443
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111453
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111467
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111481
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111493
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111507
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111521
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111535
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111549
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111563
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111577
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111591
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111653
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111667
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111681
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111695
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111711
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111725
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111739
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111755
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111769
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111783
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111799
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111813
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111827
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111841
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111855
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111869
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041111885
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111899
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111913
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111927
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111943
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111959
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111975
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041111989
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112003
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112017
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112031
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112047
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112061
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112075
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112089
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112103
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112119
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112135
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112149
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112161
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112177
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112191
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112209
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112223
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112237
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112249
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112263
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112278
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112293
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112307
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112323
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112337
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112351
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112365
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112379
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112393
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112407
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112421
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112435
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112449
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112465
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112481
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112495
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112509
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112525
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112537
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112551
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112565
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112577
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112593
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112607
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112621
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112635
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112649
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112665
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112681
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112695
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112711
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112725
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112739
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112755
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112771
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112783
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112797
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112813
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112827
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112841
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112855
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112869
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112883
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112895
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112909
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112923
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112937
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112951
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112965
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112981
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041112999
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113013
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113025
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113039
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041113197
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041113213
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041113227
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041113241
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041113255
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041113269
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041113283
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041113297
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041113311
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113325
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113339
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113353
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113367
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113383
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113397
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113412
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113425
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113441
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113455
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113471
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113485
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113499
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113513
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113533
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113547
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113561
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113577
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113591
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113605
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113619
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113633
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113647
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113661
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113675
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113689
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113703
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113717
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113731
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113745
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113765
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113779
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113793
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113807
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113823
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113837
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113853
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113867
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113881
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113895
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113909
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113923
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113939
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113951
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113965
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113981
Principal investigator 1 ModernaTX, Inc. $2,195.10 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041113999
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114013
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114027
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114041
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114057
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114073
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114089
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114103
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114119
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114131
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114147
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114161
Principal investigator 1 ModernaTX, Inc. $2,195.10 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114175
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114193
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114207
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114221
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114235
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114249
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114263
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114277
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114291
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114307
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114325
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114339
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114353
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114409
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114427
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114441
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114455
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114469
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114485
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114499
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114513
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114525
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114539
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114553
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114567
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114581
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114597
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114603
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114617
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041114631
Principal investigator 1 ModernaTX, Inc. $2,166.21 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041114645
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114659
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114675
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114687
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114703
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114717
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114733
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114745
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114759
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114777
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114791
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114803
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114817
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114831
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114847
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114862
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114877
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114889
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114903
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114917
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114935
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114951
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114965
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114979
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041114993
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115005
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115021
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041115035
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041115050
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041115063
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041115079
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041115093
Principal investigator 1 ModernaTX, Inc. $742.44 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041115107
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115121
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115135
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115149
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115163
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115177
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115191
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115205
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115221
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115239
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115253
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115265
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115279
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115295
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115309
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115323
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115335
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115351
Principal investigator 1 ModernaTX, Inc. $3,368.64 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115365
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115377
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115395
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115407
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115423
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115435
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115455
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115469
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115483
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115497
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115511
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115525
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115539
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115555
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115569
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115585
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115599
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115613
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115627
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115643
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115657
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115669
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115685
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115699
Principal investigator 1 ModernaTX, Inc. $576.84 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115713
Principal investigator 1 ModernaTX, Inc. $13.50 11/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041115727
Principal investigator 1 ModernaTX, Inc. $144.00 11/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041141789
Principal investigator 1 ModernaTX, Inc. $288.00 11/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041141805
Principal investigator 1 ModernaTX, Inc. $5,688.00 11/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041141833
Principal investigator 1 ModernaTX, Inc. $667.92 11/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041143589
Principal investigator 1 ModernaTX, Inc. $303.60 11/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041143603
Principal investigator 1 ModernaTX, Inc. $9,189.00 11/23/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041097987
Principal investigator 1 ModernaTX, Inc. $2,000.00 11/23/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098015
Principal investigator 1 ModernaTX, Inc. $2,500.00 11/23/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098059
Principal investigator 1 ModernaTX, Inc. $1,250.00 11/23/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041098073
Principal investigator 1 ModernaTX, Inc. $504.00 11/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041141819
Principal investigator 1 ModernaTX, Inc. $667.92 11/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041143621
Principal investigator 1 ModernaTX, Inc. $700.00 11/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1041143877
Principal investigator 1 ModernaTX, Inc. $4,000.00 11/17/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041143561
Principal investigator 1 ModernaTX, Inc. $4,296.32 11/17/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041143575
Principal investigator 1 Novartis Pharmaceuticals Corporation $528.26 11/16/2023 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1017225491
Principal investigator 1 ModernaTX, Inc. $841.00 11/15/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1041001707
Principal investigator 1 ModernaTX, Inc. $65,894.65 11/15/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041143547
Principal investigator 1 Janssen Research & Development, LLC $2,368.00 11/14/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129619
Principal investigator 1 Janssen Research & Development, LLC $2,368.00 11/10/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129617
Principal investigator 1 Janssen Research & Development, LLC $3,412.60 11/07/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129611
Principal investigator 1 GRT US Holding, Inc. $70.00 11/01/2023 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054187513
Principal investigator 1 Janssen Research & Development, LLC $4,345.00 11/01/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129607
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095417
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095431
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095461
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095475
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095489
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095503
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095547
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095561
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095577
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095633
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095647
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095723
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095737
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095766
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095781
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095799
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095811
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095825
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095897
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095911
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095927
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095979
Principal investigator 1 ModernaTX, Inc. $1,262.70 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096080
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096093
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096106
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096121
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096141
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096183
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096197
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096239
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096253
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096817
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096833
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096847
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096861
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096903
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096917
Principal investigator 1 ModernaTX, Inc. $1,262.70 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096977
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041096991
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097047
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097061
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097075
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097087
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097133
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097147
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097161
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097191
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097281
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097295
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097309
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097351
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097365
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097379
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097449
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097465
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097479
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097511
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097525
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097643
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097685
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097699
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097757
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097811
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097877
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097891
Principal investigator 1 ModernaTX, Inc. $742.44 10/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041097905
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094043
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094071
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094187
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094201
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094243
Principal investigator 1 ModernaTX, Inc. $1,865.16 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094365
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094379
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094449
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094478
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094495
Principal investigator 1 ModernaTX, Inc. $1,865.16 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094523
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094537
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094551
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094579
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094607
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094623
Principal investigator 1 ModernaTX, Inc. $1,865.16 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041094643
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041095053
Principal investigator 1 ModernaTX, Inc. $772.20 10/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041095359
Principal investigator 1 ModernaTX, Inc. $360.00 10/25/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041141717
Principal investigator 1 ModernaTX, Inc. $607.20 10/25/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041143279
Principal investigator 1 ModernaTX, Inc. $364.32 10/25/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041143307
Principal investigator 1 ModernaTX, Inc. $143.70 10/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1041001687
Principal investigator 1 ModernaTX, Inc. $93.00 10/23/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041001633
Principal investigator 1 ModernaTX, Inc. $63.75 10/23/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1041001697
Principal investigator 1 ModernaTX, Inc. $204.00 10/20/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041001625
Principal investigator 1 ModernaTX, Inc. $9,446.48 10/20/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041143251
Principal investigator 1 ModernaTX, Inc. $598.92 10/20/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041143265
Principal investigator 1 ModernaTX, Inc. $1,138.50 10/20/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041143291
Principal investigator 1 ModernaTX, Inc. $248.00 10/10/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041001613
Principal investigator 1 ModernaTX, Inc. $124.00 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041001643
Principal investigator 1 ModernaTX, Inc. $204.00 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041001653
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041087013
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041087027
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041087041
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041087055
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041087067
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041088217
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041088231
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041088245
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041088259
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041088437
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041088449
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041088463
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041088649
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041088665
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041088831
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041088845
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041088859
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041088873
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041088887
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041088901
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089073
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089087
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089201
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089213
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089228
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089241
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089255
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089269
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089344
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089359
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089497
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089511
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089523
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089537
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089551
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089791
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089805
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089819
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089835
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089921
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089935
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089947
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089963
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089979
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041089992
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090005
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090019
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090089
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090103
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090117
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090133
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090147
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090161
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090175
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090189
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090205
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090393
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090407
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090419
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090433
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090539
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090555
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090569
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090583
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090601
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090615
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090851
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090951
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090965
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090979
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041090995
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091011
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091281
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091295
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091311
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091585
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091599
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091685
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091699
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091713
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091727
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091741
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091827
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091841
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091857
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091873
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091885
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091899
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091913
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091929
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091941
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041091955
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092059
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092071
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092087
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092101
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092115
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092129
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092143
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092157
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092275
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092295
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092305
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092491
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092505
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092518
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092649
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092663
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092675
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092693
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092707
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092763
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092777
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092791
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092807
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092879
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092893
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092907
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092921
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041092995
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093011
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093025
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093039
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093053
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093067
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093095
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093109
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093239
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093255
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093269
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093283
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093415
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093427
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093443
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093457
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093475
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093489
Principal investigator 1 ModernaTX, Inc. $222.18 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093665
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093679
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093695
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093709
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041093723
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041094673
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041094687
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041094703
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041094717
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041094731
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041094745
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041094763
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041094779
Principal investigator 1 ModernaTX, Inc. $629.28 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041094793
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041094865
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095085
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095099
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095141
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095155
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095169
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095183
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095199
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095213
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095227
Principal investigator 1 ModernaTX, Inc. $742.44 10/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041095243
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087199
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087211
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087227
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087271
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087285
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087469
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087483
Principal investigator 1 ModernaTX, Inc. $1,865.16 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087497
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087511
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087525
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087569
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087613
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087627
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087643
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087657
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087685
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087755
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087771
Principal investigator 1 ModernaTX, Inc. $1,865.16 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087917
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087931
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087975
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087987
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041088017
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041088047
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041088061
Principal investigator 1 ModernaTX, Inc. $1,865.16 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041088077
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041088105
Principal investigator 1 ModernaTX, Inc. $2,166.21 10/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041088119
Principal investigator 1 ModernaTX, Inc. $10,000.00 10/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087185
Principal investigator 1 ModernaTX, Inc. $2,500.00 10/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087311
Principal investigator 1 ModernaTX, Inc. $3,000.00 10/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087327
Principal investigator 1 ModernaTX, Inc. $1,500.00 10/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087397
Principal investigator 1 ModernaTX, Inc. $5,000.00 10/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087412
Principal investigator 1 ModernaTX, Inc. $87.75 10/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087713
Principal investigator 1 ModernaTX, Inc. $1,250.00 10/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087727
Principal investigator 1 ModernaTX, Inc. $1,000.00 10/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087741
Principal investigator 1 ModernaTX, Inc. $3,300.00 10/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087875
Principal investigator 1 ModernaTX, Inc. $94.50 10/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041087959
Principal investigator 1 ModernaTX, Inc. $81.00 10/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041088091
Principal investigator 1 ModernaTX, Inc. $48,924.20 10/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041143321
Principal investigator 1 ModernaTX, Inc. $89,707.80 10/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041143333
Principal investigator 1 Janssen Research & Development, LLC $11,843.00 09/29/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129491
Principal investigator 1 Merck Sharp & Dohme LLC $73,196.80 09/25/2023 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults No dispute reported 06/30/2026 1042570213
Principal investigator 1 GRT US Holding, Inc. $2,000.00 09/21/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054199573
Principal investigator 1 GRT US Holding, Inc. $2,000.00 09/21/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054199591
Principal investigator 1 GRT US Holding, Inc. $4,675.00 09/21/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054199611
Principal investigator 1 GRT US Holding, Inc. $2,500.00 09/21/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054199631
Principal investigator 1 GRT US Holding, Inc. $12,000.00 09/21/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054199653
Principal investigator 1 ModernaTX, Inc. $204.00 09/21/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041001603
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 09/20/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129485
Principal investigator 1 Janssen Research & Development, LLC $2,146.00 09/20/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129487
Principal investigator 1 Janssen Research & Development, LLC $344.00 09/13/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129481
Principal investigator 1 GRT US Holding, Inc. $4,380.46 09/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF RTXGRT7039 IN ADULT SUBJECTS WITH PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 1054199555
Principal investigator 1 Janssen Research & Development, LLC $120.00 09/11/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129475
Principal investigator 1 Janssen Research & Development, LLC $400.00 09/11/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129477
Principal investigator 1 Janssen Research & Development, LLC $145.00 09/11/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129479
Principal investigator 1 ModernaTX, Inc. $500.00 09/08/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041143183
Principal investigator 1 ModernaTX, Inc. $20.25 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041079555
Principal investigator 1 ModernaTX, Inc. $1,865.16 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041079569
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041079581
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041079595
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041079609
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041079623
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041079639
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041079653
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041079669
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041079683
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041079697
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041079711
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041079725
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041079739
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041080985
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041080999
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081013
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081027
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081041
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041081113
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081127
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081141
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081155
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081161
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081175
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081193
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081209
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081223
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081237
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081251
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081263
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081277
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081291
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081305
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081321
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081335
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081349
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081363
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081377
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081391
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041081535
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041081549
Principal investigator 1 ModernaTX, Inc. $772.20 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041081563
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081581
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081595
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081609
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081623
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081637
Principal investigator 1 ModernaTX, Inc. $20.25 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041081651
Principal investigator 1 ModernaTX, Inc. $904.50 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041081666
Principal investigator 1 ModernaTX, Inc. $772.20 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041081683
Principal investigator 1 ModernaTX, Inc. $772.20 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041081695
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081727
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081741
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081755
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081769
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081783
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081797
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081811
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081825
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081839
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081853
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081869
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081883
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081897
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081911
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081925
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081940
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041081957
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041082127
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041082145
Principal investigator 1 ModernaTX, Inc. $772.20 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041082159
Principal investigator 1 ModernaTX, Inc. $772.20 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041082173
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082187
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082201
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082215
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082228
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082242
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082271
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082283
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082299
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082313
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082329
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082343
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082359
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082371
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082387
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082401
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082415
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082429
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082443
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082459
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082473
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082487
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082501
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082515
Principal investigator 1 ModernaTX, Inc. $772.20 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041082647
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041082659
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041082673
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041082687
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082701
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082715
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082729
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082743
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082757
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082771
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082787
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082799
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082813
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082829
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082843
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082857
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082873
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082887
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082901
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082915
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082931
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082945
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041082961
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083107
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083121
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083139
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083153
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083167
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083183
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083197
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083211
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083225
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083239
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083253
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083269
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083285
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083297
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083369
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083383
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083401
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083415
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083431
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083445
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083461
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083475
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083489
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041083561
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041083575
Principal investigator 1 ModernaTX, Inc. $772.20 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041083621
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041083636
Principal investigator 1 ModernaTX, Inc. $772.20 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041083649
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083665
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083679
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083693
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083707
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083721
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083735
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083749
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083763
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083777
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083791
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083807
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083821
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083837
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083853
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083869
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083883
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083899
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083911
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083927
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083939
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083954
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083969
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083983
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041083995
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084009
Principal investigator 1 ModernaTX, Inc. $1,865.16 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041084139
Principal investigator 1 ModernaTX, Inc. $20.25 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041084154
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041084169
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084183
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084197
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084213
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084227
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084239
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084253
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084267
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084283
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084297
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084311
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084327
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084343
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084357
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084373
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084389
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084403
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084415
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084429
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084445
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084459
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084473
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084487
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084499
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084515
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084529
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084545
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084559
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084575
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084589
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084603
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084617
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084631
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084647
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084661
Principal investigator 1 ModernaTX, Inc. $772.20 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041084792
Principal investigator 1 ModernaTX, Inc. $20.25 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041084807
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084835
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084849
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084863
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084881
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041084985
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041084999
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085014
Principal investigator 1 ModernaTX, Inc. $772.20 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041085145
Principal investigator 1 ModernaTX, Inc. $772.20 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041085161
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085175
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085187
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085201
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085217
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085231
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085245
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085259
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085273
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085287
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085301
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085319
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085333
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085347
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085361
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085375
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085391
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085405
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085419
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085433
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085447
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085461
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085477
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085493
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085507
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041085603
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041085617
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085645
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085659
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085673
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085689
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085705
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085717
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085733
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085747
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085761
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085773
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085791
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085803
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085817
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085833
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041085861
Principal investigator 1 ModernaTX, Inc. $772.20 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041085875
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041085889
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085903
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085917
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085931
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085945
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085961
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085975
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041085989
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086005
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086019
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086031
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086045
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086065
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086079
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086093
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086107
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086125
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086137
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086209
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086225
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086239
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086253
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086269
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086283
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086297
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086311
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086327
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086341
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086355
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086369
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086383
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086397
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086413
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086427
Principal investigator 1 ModernaTX, Inc. $772.20 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041086541
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041086555
Principal investigator 1 ModernaTX, Inc. $2,166.21 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041086569
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086583
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086597
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086611
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086625
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086639
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086697
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086712
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086729
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086735
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086759
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086773
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086789
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086805
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086818
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086831
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086845
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086859
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086875
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086887
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086901
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086915
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086929
Principal investigator 1 ModernaTX, Inc. $742.44 09/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041086943
Principal investigator 1 ModernaTX, Inc. $10,813.36 09/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041143169
Principal investigator 1 Janssen Research & Development, LLC $12,845.00 08/31/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129525
Principal investigator 1 ModernaTX, Inc. $2,290.80 08/30/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041143099
Principal investigator 1 ModernaTX, Inc. $89.70 08/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041077589
Principal investigator 1 ModernaTX, Inc. $12,738.12 08/23/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041142999
Principal investigator 1 ModernaTX, Inc. $26,910.00 08/23/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041143011
Principal investigator 1 ModernaTX, Inc. $500.00 08/16/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041143115
Principal investigator 1 Janssen Research & Development, LLC $5,381.40 08/07/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129523
Principal investigator 1 Janssen Research & Development, LLC $4,345.00 08/01/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129517
Principal investigator 1 Janssen Research & Development, LLC $5,135.00 08/01/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129519
Principal investigator 1 Janssen Research & Development, LLC $65.00 08/01/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129527
Principal investigator 1 Novartis Pharmaceuticals Corporation $29,405.68 07/25/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1017240287
Principal investigator 1 Janssen Research & Development, LLC $18,281.00 07/20/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129521
Principal investigator 1 ModernaTX, Inc. $9,749.72 07/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041142985
Principal investigator 1 Janssen Research & Development, LLC $65.00 07/05/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129515
Principal investigator 1 ModernaTX, Inc. $8,633.98 07/05/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041142973
Principal investigator 1 Janssen Research & Development, LLC $120.00 07/04/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129511
Principal investigator 1 Janssen Research & Development, LLC $2,752.00 07/04/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129513
Principal investigator 1 ModernaTX, Inc. $96,823.87 06/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041143503
Principal investigator 1 ModernaTX, Inc. $1,125.36 06/28/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041143519
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,709.23 06/27/2023 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1017225331
Principal investigator 1 ModernaTX, Inc. $500.00 06/16/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041143059
Principal investigator 1 ModernaTX, Inc. $7,707.66 06/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041142957
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041143025
Principal investigator 1 ModernaTX, Inc. $1,500.00 06/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041143043
Principal investigator 1 ModernaTX, Inc. $655.50 06/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041143071
Principal investigator 1 ModernaTX, Inc. $131.10 06/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041143085
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071687
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071701
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071717
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071731
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071743
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071757
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071771
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071785
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071801
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071815
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071831
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071847
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071859
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071875
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071893
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071911
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071925
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071939
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071953
Principal investigator 1 ModernaTX, Inc. $3,276.59 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071969
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071983
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041071997
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072011
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072025
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072039
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072055
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072069
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072083
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072097
Principal investigator 1 ModernaTX, Inc. $3,439.40 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072113
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072129
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072143
Principal investigator 1 ModernaTX, Inc. $3,439.40 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072159
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072175
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072191
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072203
Principal investigator 1 ModernaTX, Inc. $3,276.59 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072217
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072233
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072247
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072261
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072275
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072293
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072309
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072323
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072337
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072351
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072365
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072379
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072393
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072407
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072421
Principal investigator 1 ModernaTX, Inc. $904.50 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072439
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072453
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072467
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072483
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072497
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072511
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072525
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072539
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072553
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072567
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072582
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072597
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072611
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072625
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072639
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072653
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072667
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072683
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072695
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072707
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072721
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072735
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072749
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072765
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072779
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072795
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072809
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072823
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072837
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072853
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072867
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072885
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072903
Principal investigator 1 ModernaTX, Inc. $3,439.40 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072917
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072930
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072945
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072957
Principal investigator 1 ModernaTX, Inc. $904.50 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072971
Principal investigator 1 ModernaTX, Inc. $904.50 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072985
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041072997
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073009
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073023
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073035
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073049
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073061
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073073
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073093
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073109
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073123
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073137
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073151
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073165
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073179
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073195
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073207
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073223
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073237
Principal investigator 1 ModernaTX, Inc. $3,276.59 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073253
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073267
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073283
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073297
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073313
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073327
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073339
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073352
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073369
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073385
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073399
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073413
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073429
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073443
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073455
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073471
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073485
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073497
Principal investigator 1 ModernaTX, Inc. $3,276.59 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073511
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073525
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073541
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073553
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073571
Principal investigator 1 ModernaTX, Inc. $3,439.40 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073585
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073601
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073615
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073629
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073643
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073657
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073671
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073685
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073701
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073715
Principal investigator 1 ModernaTX, Inc. $3,439.40 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073727
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073741
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073757
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073771
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073785
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073799
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073815
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073829
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073843
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073857
Principal investigator 1 ModernaTX, Inc. $904.50 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073871
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073885
Principal investigator 1 ModernaTX, Inc. $904.50 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073899
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073913
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073927
Principal investigator 1 ModernaTX, Inc. $904.50 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073942
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073957
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073971
Principal investigator 1 ModernaTX, Inc. $904.50 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073983
Principal investigator 1 ModernaTX, Inc. $3,276.59 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041073997
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074011
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074025
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074039
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074053
Principal investigator 1 ModernaTX, Inc. $904.50 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074069
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074085
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074099
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074113
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074127
Principal investigator 1 ModernaTX, Inc. $3,276.59 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074141
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074155
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074169
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074183
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074197
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074209
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074223
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074237
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074253
Principal investigator 1 ModernaTX, Inc. $904.50 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074269
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074283
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074295
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074311
Principal investigator 1 ModernaTX, Inc. $904.50 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074325
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074337
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074351
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074365
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074379
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074393
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074407
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074423
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074439
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074453
Principal investigator 1 ModernaTX, Inc. $1,865.16 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074467
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074481
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074497
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074511
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074525
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074543
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074557
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074571
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074583
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074597
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074611
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074629
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074643
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074656
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074669
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074684
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074701
Principal investigator 1 ModernaTX, Inc. $904.50 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074715
Principal investigator 1 ModernaTX, Inc. $5,207.63 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074727
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074743
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074757
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074769
Principal investigator 1 ModernaTX, Inc. $3,439.40 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074785
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074799
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074811
Principal investigator 1 ModernaTX, Inc. $904.50 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074827
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074841
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074855
Principal investigator 1 ModernaTX, Inc. $3,439.40 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074869
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074885
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074900
Principal investigator 1 ModernaTX, Inc. $904.50 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074913
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074927
Principal investigator 1 ModernaTX, Inc. $904.50 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074943
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074957
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074971
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041074985
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075003
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075017
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075031
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075045
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075059
Principal investigator 1 ModernaTX, Inc. $904.50 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075075
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075091
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075105
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075119
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075133
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075147
Principal investigator 1 ModernaTX, Inc. $904.50 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075161
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075175
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075187
Principal investigator 1 ModernaTX, Inc. $3,276.59 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075203
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075217
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041075231
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041076285
Principal investigator 1 ModernaTX, Inc. $20.25 06/12/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041076299
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057153
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057167
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057181
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057195
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057207
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057221
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057235
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057251
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057265
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057279
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057293
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057307
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057321
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057335
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057349
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057365
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057381
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057395
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057411
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057425
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057439
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057453
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057467
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057481
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057495
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057510
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057525
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057539
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057553
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057567
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057581
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057597
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057609
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057624
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057637
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057651
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057665
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057679
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057691
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057703
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057717
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057729
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057743
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057757
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057771
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057785
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057795
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057810
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057823
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057837
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057851
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057865
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057945
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057957
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057973
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057987
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058001
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058015
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058029
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058043
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058057
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058071
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058086
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058103
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058119
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058137
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058151
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058165
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058179
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058193
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058211
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058223
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058237
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058251
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058265
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058281
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058295
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058307
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058321
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058337
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058352
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058366
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058381
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058395
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058409
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058423
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058437
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058451
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058463
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058477
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058493
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058507
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058523
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058537
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058553
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058569
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058585
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058599
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058615
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058629
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058643
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058657
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058671
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058687
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058699
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058715
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058731
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058744
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058757
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058773
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058787
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058801
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058809
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058823
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058837
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058851
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058865
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058881
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058897
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058911
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058923
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058937
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058953
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058967
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058981
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041058997
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059011
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059025
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059039
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059053
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059067
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059081
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059095
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059111
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059127
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059141
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059155
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059169
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059183
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059197
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059211
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059225
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059239
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059253
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059267
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059281
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059295
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059309
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059323
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059339
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059355
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059369
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059383
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059397
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059411
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059425
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059440
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059459
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059473
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059487
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059503
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059517
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059531
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059547
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059561
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059575
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059589
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059603
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059617
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059631
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059645
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059659
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059673
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059687
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059703
Principal investigator 1 ModernaTX, Inc. $1,262.70 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059719
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059734
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059749
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059763
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059777
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059791
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059805
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059819
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059834
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059849
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059863
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059877
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059891
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059905
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059919
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059933
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059949
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059963
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059977
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041059989
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060005
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060019
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060033
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060047
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060062
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060075
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060089
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060105
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060117
Principal investigator 1 ModernaTX, Inc. $1,262.70 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060133
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060147
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060161
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060175
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060189
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060203
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060217
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060229
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060243
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060259
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060273
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060287
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060301
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060315
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060327
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060341
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060357
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060371
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060383
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060403
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060417
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060433
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060449
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060463
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060479
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060493
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060507
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060521
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060535
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060549
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060563
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060577
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060591
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060607
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060621
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060635
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060649
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060661
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060677
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060691
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060705
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060719
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060733
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060747
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060767
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060781
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060793
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060807
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060821
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060835
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060851
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060865
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060879
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060893
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060907
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060921
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060936
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060951
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060965
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060979
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041060995
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061009
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061023
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061039
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061053
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061069
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061083
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061097
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061111
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061125
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061139
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061155
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061169
Principal investigator 1 ModernaTX, Inc. $13.80 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061185
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061199
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061213
Principal investigator 1 ModernaTX, Inc. $13.80 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061227
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061241
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061259
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061273
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061285
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061301
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061319
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061333
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061347
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061361
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061375
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061387
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061401
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061417
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061431
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061445
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061459
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061473
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061487
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061501
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061515
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061529
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061547
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061559
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061575
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061589
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061603
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061617
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061631
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061647
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061661
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061673
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061687
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061701
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061715
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061729
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061743
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061759
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061775
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061787
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061801
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061815
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061829
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061843
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061859
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061873
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061887
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061901
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061915
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061931
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061945
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061959
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061973
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041061987
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062003
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062017
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062031
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062045
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062057
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062069
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062083
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062099
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062112
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062131
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062147
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062161
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062177
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062191
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062206
Principal investigator 1 ModernaTX, Inc. $13.80 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062219
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062233
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062249
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062263
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062277
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062291
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062305
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062320
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062335
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062349
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062363
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062377
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062391
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062405
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062419
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062433
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062447
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062461
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062477
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062489
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062503
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062517
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062531
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062549
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062565
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062577
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062593
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062607
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062621
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062635
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062649
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062663
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062677
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062691
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062705
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062719
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062735
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062749
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062763
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062777
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062791
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062805
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062819
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062833
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062847
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062863
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062877
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062891
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062905
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062921
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062935
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062949
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062965
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062979
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041062993
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063007
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063025
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063039
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063053
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063067
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063081
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063095
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063109
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063123
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063137
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063151
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063165
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063179
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063193
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063207
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063221
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063235
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063251
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063265
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063281
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063293
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063309
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063321
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063336
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063351
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063365
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063379
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063395
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063409
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063423
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063437
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063451
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063465
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063479
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063493
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063507
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063521
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063535
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063549
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063567
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063583
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063597
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063611
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063625
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063639
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063655
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063669
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063683
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063697
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063713
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063729
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063747
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063761
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063775
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063789
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063803
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063817
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063831
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063845
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063859
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063875
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063889
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063903
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063919
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063933
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063949
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063967
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063981
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041063995
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064009
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064023
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064037
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064053
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064067
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064081
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064095
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064113
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064125
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064139
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064153
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064167
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064181
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064195
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064209
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064223
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064237
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064249
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064265
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064282
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064293
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064307
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064321
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064335
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064349
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064367
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064379
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064395
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064404
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064417
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064433
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064448
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064463
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064477
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064493
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064508
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064523
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064539
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064551
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064567
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064585
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064599
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064615
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064631
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064645
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064659
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064675
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064691
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064705
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064719
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064733
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064747
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064761
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064775
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064789
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064805
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064819
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064835
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064849
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064863
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064877
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064891
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064907
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064921
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064935
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064949
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064963
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064977
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041064993
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065007
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065021
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065039
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065053
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065065
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065077
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065091
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065105
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065119
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065133
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065147
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065162
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065178
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065191
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065207
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065223
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065237
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065251
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065265
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065279
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065291
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065307
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065321
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065337
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065350
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065365
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065379
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065391
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065405
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065421
Principal investigator 1 ModernaTX, Inc. $13.80 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065435
Principal investigator 1 ModernaTX, Inc. $742.44 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065451
Principal investigator 1 ModernaTX, Inc. $13.80 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041065467
Principal investigator 1 ModernaTX, Inc. $64,976.74 06/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041143489
Principal investigator 1 ModernaTX, Inc. $500.00 06/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057877
Principal investigator 1 ModernaTX, Inc. $500.00 06/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057886
Principal investigator 1 ModernaTX, Inc. $500.00 06/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057901
Principal investigator 1 ModernaTX, Inc. $500.00 06/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057917
Principal investigator 1 ModernaTX, Inc. $166.00 06/02/2023 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042156755
Principal investigator 1 ModernaTX, Inc. $850.00 06/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041057931
Principal investigator 1 ModernaTX, Inc. $4,000.00 06/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041141761
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041141778
Principal investigator 1 ModernaTX, Inc. $138,630.04 06/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041143461
Principal investigator 1 ModernaTX, Inc. $57,087.99 06/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041143475
Principal investigator 1 ModernaTX, Inc. $13,000.00 06/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041143533
Principal investigator 1 ModernaTX, Inc. $2,750.00 06/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041143863
Principal investigator 1 Janssen Research & Development, LLC $2,856.20 05/31/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129409
Principal investigator 1 ModernaTX, Inc. $15,900.74 05/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041142465
Principal investigator 1 ModernaTX, Inc. $3,291.90 05/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041142885
Principal investigator 1 ModernaTX, Inc. $42,841.82 05/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041142901
Principal investigator 1 ModernaTX, Inc. $150.00 05/25/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056725
Principal investigator 1 ModernaTX, Inc. $150.00 05/25/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056869
Principal investigator 1 ModernaTX, Inc. $300.00 05/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056546
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041053667
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041053679
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041053693
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041053707
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041053721
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041053735
Principal investigator 1 ModernaTX, Inc. $92.46 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041053813
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041053829
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041053843
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041053871
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041053885
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041053899
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041053915
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041053929
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041053943
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041054003
Principal investigator 1 ModernaTX, Inc. $855.60 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041054019
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041054033
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041054047
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041054061
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041054089
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041054103
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041054113
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041054127
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055225
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055239
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055253
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055267
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055281
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055299
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055341
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055353
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055367
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055385
Principal investigator 1 ModernaTX, Inc. $92.46 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055397
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055411
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055425
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055439
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055471
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055487
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055501
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055515
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055529
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055547
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055561
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055573
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055675
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055689
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055703
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055717
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055732
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055777
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055835
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055849
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055863
Principal investigator 1 ModernaTX, Inc. $92.46 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055935
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055949
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041055963
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056079
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056093
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056109
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056123
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056197
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056211
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056225
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056239
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056255
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056271
Principal investigator 1 ModernaTX, Inc. $92.46 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056301
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056317
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056333
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056347
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056361
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056447
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056459
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056473
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056491
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056504
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056517
Principal investigator 1 ModernaTX, Inc. $1,262.70 05/22/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041056531
Principal investigator 1 ModernaTX, Inc. $65,857.74 05/17/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041142380
Principal investigator 1 ModernaTX, Inc. $67,740.75 05/17/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041142393
Principal investigator 1 ModernaTX, Inc. $64,529.49 05/17/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041142407
Principal investigator 1 ModernaTX, Inc. $45,880.17 05/17/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041142421
Principal investigator 1 ModernaTX, Inc. $12,041.88 05/17/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041142435
Principal investigator 1 ModernaTX, Inc. $20,263.92 05/17/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041142449
Principal investigator 1 Amgen Inc. $7,873.60 05/12/2023 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
P3 AD Adult Combo TCS No dispute reported 06/30/2026 1029653771
Principal investigator 1 Eli Lilly and Company $236,584.00 05/09/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1038095409
Principal investigator 1 ModernaTX, Inc. $360.00 05/03/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041141329
Principal investigator 1 ModernaTX, Inc. $15,540.20 05/03/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041142367
Principal investigator 1 ModernaTX, Inc. $97,875.48 04/26/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041142857
Principal investigator 1 Janssen Research & Development, LLC $73,408.00 04/24/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129407
Principal investigator 1 ModernaTX, Inc. $1,920.00 04/21/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041141633
Principal investigator 1 ModernaTX, Inc. $250.00 04/19/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041142353
Principal investigator 1 ModernaTX, Inc. $3,456.00 04/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041141285
Principal investigator 1 ModernaTX, Inc. $172.00 04/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041141299
Principal investigator 1 ModernaTX, Inc. $100.00 04/14/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041141315
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040305
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040319
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040333
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040347
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040361
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040375
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040391
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040405
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040417
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040433
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040447
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040459
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040473
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040487
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040502
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040519
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040531
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040545
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040559
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040575
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040589
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040603
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040617
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040631
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040645
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040661
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040675
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040689
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040717
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040731
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040745
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040759
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040773
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040791
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040807
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040821
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040835
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040849
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040863
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040877
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040895
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040907
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040921
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040935
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040949
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040969
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040983
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040997
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041013
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041027
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041041
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041055
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041069
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041083
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041097
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041111
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041129
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041143
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041157
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041171
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041187
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041201
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041215
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041229
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041243
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041257
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041277
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041291
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041305
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041319
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041333
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041347
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041363
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041377
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041393
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041407
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041423
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041439
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041453
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041465
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041479
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041495
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041509
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041523
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041537
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041551
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041563
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041577
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041593
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041609
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041623
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041637
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041651
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041665
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041679
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041695
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041709
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041723
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041737
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041751
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041765
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041779
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041793
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041807
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041823
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041837
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041851
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041865
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041880
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041895
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041911
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041925
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041939
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041953
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041967
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041981
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041041991
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042001
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042017
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042029
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042043
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042057
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042071
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042085
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042099
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042113
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042129
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042143
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042157
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042171
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042185
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042199
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042213
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042229
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042243
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042259
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042273
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042287
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042301
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042315
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042329
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042339
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042353
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042361
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042375
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042389
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042405
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042417
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042429
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042443
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042457
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042471
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042481
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042495
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042503
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042517
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042531
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042545
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042557
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042571
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042587
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042601
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042617
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042633
Principal investigator 1 ModernaTX, Inc. $1,900.00 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042649
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042663
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042677
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042691
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042707
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042721
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042735
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042751
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042765
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042781
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042793
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042807
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042823
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042837
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042851
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042863
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042879
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042893
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042907
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042923
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042937
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042951
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042965
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042983
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041042997
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043011
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043025
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043039
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043055
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043071
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043085
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043099
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043119
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043135
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043147
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043161
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043173
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043189
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043207
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043219
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043231
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043243
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043257
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043273
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043285
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043301
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043315
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043331
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043345
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043361
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043373
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043389
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043403
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043417
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043431
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043445
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043459
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043473
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043487
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043501
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043515
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043529
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043543
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041043557
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041044835
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041044849
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041044865
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041044881
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041044895
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041044907
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041044921
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041044935
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041044949
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041044965
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041044979
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041044993
Principal investigator 1 ModernaTX, Inc. $213.90 04/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041045009
Principal investigator 1 ModernaTX, Inc. $31,763.49 04/07/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041142335
Principal investigator 1 ModernaTX, Inc. $1,221.30 04/03/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040703
Principal investigator 1 ModernaTX, Inc. $20,959.80 03/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041142323
Principal investigator 1 ModernaTX, Inc. $117,928.26 03/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041142813
Principal investigator 1 Janssen Research & Development, LLC $23,213.40 03/23/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129365
Principal investigator 1 ModernaTX, Inc. $166.50 03/17/2023 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042156753
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033279
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033289
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033299
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033311
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033323
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033332
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033343
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033353
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033363
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033373
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033383
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033467
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033477
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033487
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033497
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033509
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033521
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033531
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033541
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033551
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033561
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033571
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033585
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033595
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033605
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033615
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033625
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033635
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033647
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033657
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033667
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033677
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033687
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033699
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033709
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033719
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033729
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033741
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033801
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033813
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033825
Principal investigator 1 ModernaTX, Inc. $1,262.70 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033835
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033845
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033855
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033865
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033877
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041033887
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034093
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034105
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034115
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034125
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034133
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034145
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034157
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034313
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034325
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034335
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034345
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034355
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034365
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034375
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034385
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034397
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034409
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034419
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034431
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034441
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034451
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034461
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034471
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034481
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034491
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034503
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034515
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034525
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034535
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034545
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034555
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034565
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034739
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034749
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034759
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034769
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034781
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034791
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034801
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034811
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034969
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034979
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034989
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041034999
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035009
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035019
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035029
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035035
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035045
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035053
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035063
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035075
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035085
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035093
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035105
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035115
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035157
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035167
Principal investigator 1 ModernaTX, Inc. $1,262.70 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035177
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035188
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035199
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035209
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035397
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035407
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035415
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035425
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035435
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035633
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035649
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035663
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035679
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035693
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035707
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035721
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035737
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035749
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035763
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035953
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035969
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035983
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041035997
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036011
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036021
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036035
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036053
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036067
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036079
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036095
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036109
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036365
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036379
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036393
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036407
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036417
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036429
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036441
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036455
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036469
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036485
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036499
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036515
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036527
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036541
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036555
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036569
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036585
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036601
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036611
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036625
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036639
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041036653
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037057
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037071
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037087
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037103
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037117
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037131
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037145
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037159
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037173
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037187
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037201
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037215
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037229
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037243
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037257
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037271
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037285
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037299
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037313
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037327
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037349
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037363
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037377
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037391
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037503
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037519
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037533
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037547
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037561
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037575
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037589
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037605
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037619
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037631
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037645
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037659
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037675
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037691
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037705
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037719
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037733
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037747
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037763
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041037777
Principal investigator 1 ModernaTX, Inc. $1,262.70 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038083
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038097
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038111
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038125
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038139
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038153
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038167
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038181
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038343
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038357
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038371
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038385
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038399
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038415
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038429
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038443
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038459
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038475
Principal investigator 1 ModernaTX, Inc. $1,262.70 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038488
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038505
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038519
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038533
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038749
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038765
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038779
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038793
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038809
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038825
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038841
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038855
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038871
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038885
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038899
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038911
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038925
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038941
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038955
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038969
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038983
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041038999
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039013
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039027
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039043
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039062
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039075
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039091
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039105
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039507
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039523
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039537
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039551
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039565
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039579
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039595
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039609
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039623
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039637
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039651
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039665
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039679
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039695
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039709
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039725
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039741
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039755
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039769
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039783
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039799
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039813
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039827
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039841
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039853
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041039969
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040053
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040065
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040079
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040093
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040107
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040123
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040137
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040151
Principal investigator 1 ModernaTX, Inc. $1,262.70 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040165
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040179
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040193
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040207
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040221
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040235
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040249
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040263
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040275
Principal investigator 1 ModernaTX, Inc. $742.44 03/13/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041040291
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022715
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022727
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022737
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022747
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022757
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022767
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022779
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022791
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022801
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022811
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022823
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022833
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022843
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022853
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022863
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022873
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022885
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022895
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022907
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022917
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022927
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022941
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041022951
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023001
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023013
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023023
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023033
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023043
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023053
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023065
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023077
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023087
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023097
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023107
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023117
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023127
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023137
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023147
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023159
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023171
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023183
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023193
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023203
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023675
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023685
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023695
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023707
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023713
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023723
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023737
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023745
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023755
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023765
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023775
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023785
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024045
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024057
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024067
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024079
Principal investigator 1 ModernaTX, Inc. $1,262.70 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024089
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024099
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024109
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024119
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024211
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024221
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024233
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024245
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024255
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024265
Principal investigator 1 ModernaTX, Inc. $1,262.70 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024275
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024285
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024295
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024305
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024315
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024325
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024335
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024347
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024357
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024365
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024375
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024387
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024397
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024407
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024417
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024427
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024437
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024447
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024458
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024473
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024483
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024493
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024503
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024513
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024523
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024535
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024543
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024555
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024565
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024577
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024587
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024597
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024607
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024617
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024627
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024639
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024649
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024661
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024961
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024971
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024983
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041024993
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025005
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025015
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025025
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025035
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025045
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025055
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025065
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025077
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025087
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025097
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025107
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025117
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025130
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025141
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025151
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025163
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025173
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025183
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025193
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025203
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025215
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025227
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025239
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025249
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025259
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025269
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025279
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025289
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025299
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025309
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025319
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025330
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025635
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025647
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025657
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025667
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025677
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025687
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025697
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025710
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025721
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025731
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025741
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025753
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025763
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025773
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025783
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025793
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025805
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025815
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025825
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025837
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025847
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025857
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025867
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025877
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025889
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025899
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025909
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025919
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025961
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025971
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025981
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041025993
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026005
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026015
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026025
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026035
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026045
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026055
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026067
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026077
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026087
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026097
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026107
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026119
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026131
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026141
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026151
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026159
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026173
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026183
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026193
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026203
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026215
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026225
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026235
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026245
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026255
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026375
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026385
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026395
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026405
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026415
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026425
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026435
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026445
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026459
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026469
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026479
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026489
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026499
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026509
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026521
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026533
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026543
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026553
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026565
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026575
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026583
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026593
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026603
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026615
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026627
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026637
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026647
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026687
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026699
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026709
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026721
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026733
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026743
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026753
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026765
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026775
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026785
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026795
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026805
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026815
Principal investigator 1 ModernaTX, Inc. $1,262.70 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026827
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026837
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026847
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026859
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026869
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026879
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026889
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026899
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026909
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026921
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026931
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026941
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026951
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041026961
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027033
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027045
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027055
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027065
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027075
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027085
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027095
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027105
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027115
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027125
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027135
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027149
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027159
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027169
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027375
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027385
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027397
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027405
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027417
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027427
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027437
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027447
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027457
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027467
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027479
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027491
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027501
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027511
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027521
Principal investigator 1 ModernaTX, Inc. $1,262.70 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027531
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027541
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027551
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027633
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027643
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027653
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027665
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027709
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027719
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027729
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027739
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027749
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027759
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027771
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027781
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027789
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027803
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027813
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027823
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027833
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027843
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027853
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027863
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027875
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027885
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027895
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027905
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027917
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027927
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041027938
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028095
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028199
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028209
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028219
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028231
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028239
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028251
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028261
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028271
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028281
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028291
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028302
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028311
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028321
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028334
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028345
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028353
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028363
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028373
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028383
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028393
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028403
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028413
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028427
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028437
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028447
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028455
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028465
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028475
Principal investigator 1 ModernaTX, Inc. $1,262.70 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028485
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028495
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028505
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028515
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028525
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028535
Principal investigator 1 ModernaTX, Inc. $1,262.70 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028547
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028557
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028569
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028579
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028589
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028599
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028609
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028619
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028629
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028639
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028649
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028659
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028671
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028681
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028693
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028703
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028713
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028725
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028735
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028745
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028755
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028765
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028777
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028787
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028797
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028807
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028819
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028829
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028843
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028853
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028863
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028873
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028883
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028893
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028903
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028913
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028921
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028931
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028939
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028949
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028959
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028969
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028979
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028989
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041028999
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029013
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029023
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029033
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029043
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029053
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029065
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029095
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029107
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029115
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029127
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029137
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029147
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029157
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029167
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029177
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029185
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029197
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029207
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029217
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029227
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029239
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029249
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029259
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029269
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029279
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029291
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029301
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029313
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029323
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029433
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029445
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029453
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029649
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029659
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029669
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029681
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029691
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029701
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029711
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029721
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029733
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029743
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029753
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029929
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029941
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029951
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029963
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029973
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029983
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041029993
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030003
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030015
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030025
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030037
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030047
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030057
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030067
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030077
Principal investigator 1 ModernaTX, Inc. $4,371.15 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030089
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030099
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030109
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030119
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030131
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030141
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030151
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030161
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030169
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030179
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030191
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030203
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030213
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030223
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030233
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030243
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030253
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030263
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030273
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030285
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030335
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030347
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030359
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030369
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030379
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030389
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030399
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030409
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030419
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030431
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030441
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030451
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030463
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030475
Principal investigator 1 ModernaTX, Inc. $845.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030485
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030495
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030505
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030515
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030527
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030537
Principal investigator 1 ModernaTX, Inc. $1,262.70 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030547
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030559
Principal investigator 1 ModernaTX, Inc. $742.44 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030569
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030579
Principal investigator 1 ModernaTX, Inc. $638.94 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041030609
Principal investigator 1 ModernaTX, Inc. $27,283.30 02/24/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041142799
Principal investigator 1 Janssen Research & Development, LLC $21,212.00 02/17/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129359
Principal investigator 1 ModernaTX, Inc. $76,856.50 02/10/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041142785
Principal investigator 1 ModernaTX, Inc. $650.00 02/06/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041023213
Principal investigator 1 ModernaTX, Inc. $15,385.29 02/03/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041142307
Principal investigator 1 ModernaTX, Inc. $3,000.00 02/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041020335
Principal investigator 1 ModernaTX, Inc. $1,250.00 02/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041020493
Principal investigator 1 ModernaTX, Inc. $1,200.00 02/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041020501
Principal investigator 1 ModernaTX, Inc. $2,000.00 02/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041020859
Principal investigator 1 ModernaTX, Inc. $2,500.00 02/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041021251
Principal investigator 1 ModernaTX, Inc. $11,575.00 02/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041021525
Principal investigator 1 ModernaTX, Inc. $3,000.00 02/02/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041021743
Principal investigator 1 ModernaTX, Inc. $500.00 02/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041141617
Principal investigator 1 ModernaTX, Inc. $203,976.50 02/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041142757
Principal investigator 1 Janssen Research & Development, LLC $1,458.80 01/31/2023 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986129357